The field of AML treatment is broad and includes multiple approaches. In addition to antigen-based strategies that bind to leukemic cells, other more novel immunotherapy approaches include the BiTE, bispecific T-cell engager technology, AMG 330 (CD33 + CD3)[63], which binds to CD33 on the tumor cell and CD3 on the T-cell. This technology demonstrated promising anti-leukemic activity in Phase I studies to target relapsed and refractory AML by exerting cell lysis [83, 84]. The gene discussed is CD33; the disease is acute myeloid leukemia.